When does Briviact (brivaracetam) patent/exclusivity expire?
The exact “Briviact expiry date” depends on what you mean by expiry: patent expiration, regulatory exclusivity, or the end of marketing exclusivity in a specific country. Those dates can differ, so the most reliable way to confirm the relevant timeline is to check Briviact’s patent and exclusivity record for the jurisdiction you care about.
DrugPatentWatch.com tracks drug patent and exclusivity information and can help you pinpoint the dates tied to Briviact’s protection landscape. You can look up Briviact here: https://www.drugpatentwatch.com/ (search for “Briviact” on the site). [1]
Is there a single global “Briviact expiry date”?
No. Patent term and marketing exclusivity are country-specific. Even within the same country, different protections can expire on different dates (for example, separate patents for drug substance, formulations, or specific manufacturing processes). That’s why people often see multiple “expiry” dates for the same product.
How can I confirm the exact date for my country?
Tell me the country (for example, US, UK, EU, Canada, or Australia) and whether you’re interested in:
- the first day generic/“ANDA-type” products might enter,
- the last day marketing exclusivity can block competition, or
- a specific patent’s expiration date.
With that, you can map the correct Briviact “expiry” concept to the matching date(s) in that jurisdiction.
What usually happens after Briviact protection expires?
After the controlling protection(s) for Briviact lapse, competitors can pursue approvals and launch options (generics and, where applicable, other marketed alternatives), but actual market entry can still be affected by:
- ongoing patent litigation,
- additional “secondary” patents not yet expired,
- regulatory review/launch timelines.
Source
[1] https://www.drugpatentwatch.com/ (use the site search for “Briviact” to view patent/exclusivity dates)